Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Pharvaris N.V. (PHVS)

38.02 +1.75 (+4.82%)
As of 3:17:16 PM EDT. Market Open.
Trade PHVS on Coinbase
Chart Range Bar
Loading chart for PHVS
  • Previous Close 36.27
  • Open 36.27
  • Bid 27.41 x 100
  • Ask 47.46 x 100
  • Day's Range 35.80 - 38.13
  • 52 Week Range 20.65 - 38.13
  • Volume 480,288
  • Avg. Volume 486,491
  • Market Cap (intraday) 2.669B
  • Beta (5Y Monthly) -2.33
  • PE Ratio (TTM) --
  • EPS (TTM) -3.03
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 49.52

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

pharvaris.com

148

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PHVS
37.01%
S&P 500 (^GSPC)
11.89%

1-Year Return

PHVS
64.45%
S&P 500 (^GSPC)
18.44%

3-Year Return

PHVS
103.64%
S&P 500 (^GSPC)
75.02%

5-Year Return

PHVS
104.63%
S&P 500 (^GSPC)
70.73%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -46.74M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

38.40
49.52 Average
38.02 Current
75.80 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 51 -> 52

Statistics

View More

Valuation Measures

Annual
As of 8/21/2026
  • Market Cap

    2.54B

  • Enterprise Value

    2.17B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    7.25

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.32%

  • Return on Equity (ttm)

    -70.46%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -170.92M

  • Diluted EPS (ttm)

    -3.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    318.28M

  • Total Debt/Equity (mrq)

    0.22%

  • Levered Free Cash Flow (ttm)

    -90.36M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

38.02 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: